Tamibarotene is an investigational drug.
There have been 11 clinical trials for Tamibarotene.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 8th 2021.
The most common disease conditions in clinical trials are Leukemia, Myelodysplastic Syndromes, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are CytRx, Syros Pharmaceuticals, and Cephalon.
There are four hundred and seventeen US patents protecting this investigational drug and four international patents.